Document is current
Any future updates will be listed below
-
Authors
Gómez-Peregrina, David https://orcid.org/0000-0003-1126-897X
Serrano, César
- License Information
-
More Information
Article History
Received: 2 December 2025
Revised: 7 January 2026
Accepted: 12 January 2026
First Online: 5 February 2026
Competing interests
: C.S. has received research funding (institution) from IDRX and Blueprint; consulting fees (advisory role) from Bayer, NewBay, IDRX, Cogent, and Deciphera; payment for lectures from Roche, PharmaMar, and Deciphera; and travel grants from Gilead, PharmaMar, Pfizer, and Bayer AG. D.G.P. has no conflicts to declare.
